Retatrutide· 10mg
Triple-agonist GLP-1 / GIP / glucagon. The most aggressive fat-loss peptide in trials.
Individual
$98.10
label.overview
Investigational triple-agonist on GLP-1, GIP, and glucagon receptors. Phase II data shows mean weight reduction approaching 24% at 48 weeks at the highest dose.
Retatrutide (LY-3437943) is a unipeptide that simultaneously activates GLP-1, GIP, and glucagon receptors. The glucagon arm drives basal energy expenditure upward — a mechanism the dual-agonists do not have.
Mechanism
Triple-agonist: GLP-1 + GIP + glucagon receptors.
Researcher notes
- • Titration: Week 1–4: 2 mg once weekly; Week 5–8: 4 mg once weekly; Week 9–12: 6–8 mg once weekly.
- • Maintenance: 8–12 mg once weekly, subcutaneous.
- • Always titrate from the lowest dose to manage GI tolerability; rotate injection sites.
Mechanism
Triple-agonist: GLP-1 + GIP + glucagon receptors.
Half-life
~6 days
Reconstitution
Add 2 mL bacteriostatic water to the 20 mg vial. Each 0.1 mL = 1 mg.
Storage
Lyophilized: 2–8 °C. Reconstituted: 2–8 °C, use within 30 days.
Reconstitution & general research dosing
- Reconstitution
- 2 mL bacteriostatic water into a 10 mg vial → 5 mg/mL (each 0.1 mL = 500 mcg).
- Typical research dose
- Research dose-finding ranges of ~2–12 mg per week, titrated upward over several weeks.
- Frequency
- Once weekly, subcutaneous.
- Vial duration
- A 10 mg vial lasts ~5 weeks at 2 mg/week, ~2 weeks at 5 mg/week, and ~1 week at the upper 8–12 mg titration window. At low weekly doses, the 28-day reconstituted-use window is the practical cap — reconstitute in halves if dosing slower than 2.5 mg/week.
- Storage
- Refrigerate 2–8 °C after reconstitution; use within 28 days. Lyophilized vials freezer-stable.
- Always titrate from the lowest dose to manage GI tolerability in research models.
- Rotate injection sites in research animals to minimize local irritation.